Forty Seven Inc.
1661 Page Mill Road
About Forty Seven Inc.
Forty Seven Inc., a new biotechnology company specializing in cancer immunotherapy, is powering two upcoming anti-cancer studies with the Medidata Clinical Cloud®.
Forty Seven is named after the CD47 tumor cell protein that its lead molecule, Hu5F9-G4–an experimental monoclonal cancer drug–aims to attack. The biotech is embarking on a series of clinical trials to test its safety and efficacy in solid tumor and blood cancers. As part of these efforts, Forty Seven is using Rave in two of its upcoming Phase I and Phase II trials to streamline study operations, improve data quality and accessibility, and speed decision-making processes.
CEO: Jonathan MacQuitty, Ph.D., M.B.A.
Chief Business Officer: Craig Gibbs, PhD., M.B.A.
Chief Medical Officer: Chris Takimoto M.D. Ph.D.
Chief Patent Officer: Norm Kruse PhD., J.D
23 articles with Forty Seven Inc.
bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy
bluebird bio, Inc. and Forty Seven, Inc. announced that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based conditioning regimen, FSI-174 plus magrolimab, with bluebird’s ex vivo lentiviral vector hematopoietic stem cell gene therapy platform.
Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in Combination with LentiGlobin
Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual MeetingForty Seven to Host Investor Event and Webcast on December 9, 2019
Forty Seven, Inc. announced that updated data from its ongoing Phase 1b study evaluating magrolimab in combination with azacitidine for the treatment of myelodysplastic syndrome and acute myeloid leukemia, including additional efficacy and durability data from a larger number of patients, will be presented in an oral presentation at the 61st American Society of Hematology Annual Meeting, which is taking place Dec 7-10, 2019 in Orlando, Florida.
Forty Seven Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2019 to report its third quarter 2019 financial results and provide a corporate update..
Forty Seven, Inc. and Ono Pharmaceutical Co., Ltd. Sign Regional License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Select Countries in Southeast Asia
Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, and Ono Pharmaceutical Co., Ltd. today announced an exclusive license agreement for the development, manufacture and commercialization of 5F9, Forty Seven’s monoclonal antibody against CD47.
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
Durable Responses Observed in DLBCL and Indolent Lymphoma; Median Duration of Response Not Yet Reached
Forty Seven Inc. and Acerta Enter Collaboration to Evaluate Novel Immuno-Oncology Triple Combination in Diffuse Large B-cell Lymphoma
Forty Seven Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence
The triple combination therapy does not use a chemotherapy agent in its experimental treatment for an aggressive blood cancer.
10/8/2018Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.
It’s been a pretty good year for biotech initial public offerings (IPOs), with two Bay Area biotechs marking numbers eight and nine for the area.
Forty Seven, Inc. Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Forty Seven, Inc. announced proof-of-concept data from two separate clinical trials of 5F9: an ongoing Phase 1b/2 trial evaluating 5F9 in combination with rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma (r/r NHL) and a Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) trial in patients with advanced solid tumors.
Forty Seven, Inc. Granted Fast Track Designation for 5F9 for the Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Forty Seven, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to its lead candidate, 5F9, for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
Forty Seven Inc. is a clinical-stage company focused on developing checkpoint therapies to activate macrophages in the fight against cancer
Ms. Rhoads brings over 20 years of corporate and financial management expertise in the life sciences and healthcare industry.
Forty Seven to Collaborate with Merck KGaA, Darmstadt, Germany, on a Novel Immuno-Oncology Combination for Ovarian Cancer
Forty Seven today announced an agreement with Merck KGaA, Darmstadt, Germany to conduct a Phase 1b clinical trial combining Hu5F9-G4 with avelumab* in patients with ovarian cancer.
Forty Seven today announced an agreement with Genentech for Genentech to sponsor two clinical trials.
10/25/2017Rumor is there's a new approach to fighting cancer in town.
The round was led by new investors as well as existing investors.